Patent: 10,093,934
✉ Email this page to a colleague
Summary for Patent: 10,093,934
| Title: | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
| Abstract: | The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer. |
| Inventor(s): | Purschke; Werner (Berlin, DE), Jarosch; Florian (Berlin, DE), Eulberg; Dirk (Berlin, DE), Klussmann; Sven (Berlin, DE), Buchner; Klaus (Berlin, DE), Maasch; Christian (Berlin, DE), Dinse; Nicole (Berlin, DE), Zboralski; Dirk (Berlin, DE) |
| Assignee: | NOXXON Pharma AG (Berlin, DE) |
| Application Number: | 15/201,477 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,093,934
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-09-09 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2030-09-09 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2030-09-09 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2030-09-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
